View Financial HealthParkerVision 配当と自社株買い配当金 基準チェック /06ParkerVision配当金を支払った記録がありません。主要情報n/a配当利回り-15.3%バイバック利回り総株主利回り-15.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Nov 22ParkerVision, Inc. announced that it expects to receive $3.461132 million in fundingParkerVision, Inc. entered into subscription agreements with accredited investors on November 21, 2025. Pursuant to the agreement the Investors agreed to purchase an aggregate of 16,481,579 shares of the Company’s common stock, par value $0.01 per share, at a purchase price of $0.21 per share, for an aggregate purchase price of approximately $3,461,132. The closing of the transaction is expected to occur on November 24, 2025.お知らせ • Aug 19ParkerVision, Inc., Annual General Meeting, Sep 30, 2025ParkerVision, Inc., Annual General Meeting, Sep 30, 2025.お知らせ • Apr 22Parkervision, Inc. Announces Resignation of Sanford Litvack from Board of Directors, and from Audit and Compensation Committees, Effective April 15, 2025ParkerVision, Inc. announced thatoOn April 15, 2025, Mr. Sanford Litvack resigned from Board of Directors, and from the Audit and Compensation Committees on which he served.お知らせ • Sep 07ParkerVision, Inc. Announces Appellate Court Overturns District Court in A Precedential Ruling, Sends Parkervision V Qualcomm Back to Florida for TrialParkerVision, Inc. announced that the United States Court of Appeals for the Federal Circuit (CAFC) has issued a favorable ruling in ParkerVision v. Qualcomm (Case No. 2022-1755). The CAFC upheld ParkerVision's position on each of the appealed issues and has sent the case back to the Middle District of Florida (District Court) for trial. The CAFC opinion: Reversed the District Court's Daubert ruling, which had deemed ParkerVision's expert report inadmissible and likewise vacated the District Court's grant of summary judgement of non-infringement of the transmitter claims which was based on the exclusion of ParkerVision's infringement experts. The District Court had dismissed the evidence supporting ParkerVision's patent infringement claims because the expert did not create his own simulations of Qualcomm's accused radio frequency chips. However, the CAFC found that the District Court abused its discretion in excluding the testimony of ParkerVision's validity expert, stating "the district court should have left it to jurors to evaluate the correctness of facts underlying an expert's testimony". This reversal reinstates ParkerVision's expert report, allowing the Company to present its infringement claims against Qualcomm to a jury. Vacated the District Court's summary judgement ruling, which had barred ParkerVision from asserting its radio frequency receiver patents in this case. The lower court had based its decision on the argument that these patents are essentially the same as other ParkerVision receiver patents previously asserted against Qualcomm in 2011. The CAFC found that the District Court erred in its determination that the asserted receiver claims did not have a scope that is materially different from the claims at issue in the 2011 case and remanded for further consideration. Reversed the District Court's application of collateral estoppel, which prevented ParkerVision from defending the validity of its ‘940 patent using arguments it previously presented to the Patent Trial and Appeal Board (PTAB) and the CAFC. These arguments had been successful in a prior inter partes review (IPR) proceeding initiated by Qualcomm in 2015 which delayed the patent infringement case until 2019. The CAFC has remanded the case to the U.S. District Court for the Middle District of Florida, ordering the reopening of the original case (Case No. 6:14-cv-00687). ParkerVision initiated this case against Qualcomm in the Federal District Court in Orlando, Florida, in May 2014 while awaiting a final decision on a separate 2011 patent infringement case involving different receiver patents. The case experienced several delays due to Qualcomm's IPR challenges to patent validity and court closures caused by the pandemic. By May 2021, all final pre-trial motions had been filed. With courts reopening in 2022, the District Court held a pre-trial motion hearing in January 2022, signaling preparation for a near-term jury trial. However, in March 2022, the District Court issued orders in Qualcomm's favor on all motions, effectively barring ParkerVision from presenting the case to a jury. The court subsequently closed the case file. ParkerVision appealed three of the District Court's rulings to the CAFC, and by the end of 2022, both parties had submitted their appellate briefs and replies. In November 2023, the CAFC permitted oral arguments to support these briefs. However, in July 2024, the CAFC found that it lacked proper jurisdiction over the case because the District Court had not issued a final order on Qualcomm's counterclaims for invalidity. Subsequently, the parties filed a joint motion with the District Court. On August 1, 2024, the District Court issued an order dismissing Qualcomm's invalidity counterclaims, without prejudice, clearing the way for the CAFC to proceed with its ruling on the appeal.お知らせ • Sep 02ParkerVision, Inc., Annual General Meeting, Oct 28, 2024ParkerVision, Inc., Annual General Meeting, Oct 28, 2024.お知らせ • Aug 03ParkerVision, Inc., Annual General Meeting, Sep 15, 2023ParkerVision, Inc., Annual General Meeting, Sep 15, 2023, at 11:00 Eastern Standard Time. Agenda: To elect two Class I directors until the term of Class I directors ends in 2026 and to elect one Class II director until the term of Class II directors ends in 2024; to approve, on an advisory basis, the company’s named executive officer compensation ("Say on Pay"); to ratify the selection of MSL, P.A. as the company’s independent registered public accounting firm for the year ending December 31, 2023; and to discuss other matters.お知らせ • Jun 27ParkerVision, Inc. Appoints Lewis (Lew) H. Titterton as Class II DirectorParkerVision, Inc. announced that it has appointed Mr. Lewis (Lew) H. Titterton, Jr. as a Class II director to fill a vacancy on the company's board of directors. Mr. Titterton previously served on the ParkerVision board from September 2018 until April 2019 when he resigned due to family medical issues. Mr. Titterton has served on the board of directors of Anixa Biosciences since July 2017, including as lead independent director since July 2018 and chairman of the board from 2012 to 2016. His background is in high technology with an emphasis on health care and he was the chairman of the board of directors of NYMED, Inc. from 1989 until October 2018. Mr. Titterton founded MedE America, Inc. in 1986 and was the chief executive officer of Management and Planning Services, Inc. from 1978 to 1986. He holds an MBA from the State University of New York at Albany, and a B.A. degree from Cornell University.お知らせ • Jan 24ParkerVision, Inc. announced that it has received $0.835 million in fundingOn January 23, 2023, ParkerVision, Inc. closed the transaction. The transaction included participation from five investors.お知らせ • Jan 10ParkerVision, Inc. announced that it has received $1 million in fundingOn January 9, 2023, ParkerVision, Inc. closed the transaction. The transaction included participation from a single investorお知らせ • Dec 16ParkerVision, Inc. announced that it has received $0.2 million in fundingOn December 14, 2022, ParkerVision, Inc. closed the transaction. The transaction included participation from a single investor.お知らせ • Nov 01ParkerVision, Inc. Appoints Sanford M. Litvack as Board of DirectorParkerVision, Inc. announced that it has named Sanford (Sandy) Litvack to its Board of Directors, expanding the Board to five members, four of whom are independent. Mr. Litvack is a partner with Chaffetz Lindsey LLP and has a broad corporate litigation background, handling a wide array of complex matters, including patent and other intellectual property issues. Litvack served as Assistant Attorney General in charge of the Antitrust Division of the Department of Justice and was selected by President George W. Bush to serve as a member of the Antitrust Modernization Commission. In addition to his courtroom experience, Mr. Litvack spent a decade at the Walt Disney Company holding various roles from general counsel to chief of corporate operations and vice chairman of the board of directors. He is also a former director of Hewlett Packard. Mr. Litvack currently serves on the board of directors for L Catterton Asia Acquisition Corp., a special purpose acquisition company.お知らせ • Aug 18ParkerVision, Inc. announced that it has received $1.6675 million in fundingOn August 17, 2022, ParkerVision, Inc. closed the transaction. The transaction included participation from 13 investors.お知らせ • Aug 03ParkerVision, Inc., Annual General Meeting, Sep 16, 2022ParkerVision, Inc., Annual General Meeting, Sep 16, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect two Class III members of the Board to hold office until the third ensuing annual meeting and until his respective successor is duly elected and qualified; to approve an amendment to the amended and restated articles of incorporation of the company, as amended, to increase the number of authorized shares of common stock from 150,000,000 shares to 175,000,000 shares; to ratify the appointment of MSL, P.A. as the company's independent registered public accounting firm for the year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.お知らせ • Jul 02ParkerVision, Inc. announced that it has received $0.35 million in funding from Forge Trust Company, and other investorsParkerVision, Inc. announced that it has entered into a purchase agreement for a private placement of 8% unsecured convertible promissory notes for gross proceeds of $350,000on June 30, 2022. The transaction included participation from Forge Trust Company for $200,000, The Trustee of the Judson Dean LaCapra Revocable Trust for $25,000, individual investors John F. Levy for $100,000, Wilhem Boulay for $25,000. The notes bear interest at a fixed rate of 8% per annum and is payable quarterly either in cash, shares of common stock, or a combination thereof at the company's option, subject to certain equity conditions, on the 15th of April, July, October, and January of each year during the five year term of the notes, expiring June 30, 2027. The notes are convertible at any time and from time to time by the Holders into shares of common stock at a fixed conversion price of $0.13 per share. The company issued securities in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder.お知らせ • Jun 03ParkerVision, Inc. announced that it has received $0.76 million in funding from Alpine Partners (Bvi), L.P., Thomas Staz Revocable TrustParkerVision, Inc. announced that it has entered into a note and warrant purchase agreement for a private placement of 8% unsecured convertible promissory notes for gross proceeds of $760,000 on June 2, 2022. The transaction included participation from Thomas Staz Revocable Trust for $65,000, Alpine Partners (BVI) LP for $500,000, individual investors, Harold Wrobel for $130,000 and Ronald T. Bevans, Jr. for $65,000. The notes bear interest at a fixed rate of 8% per annum and is payable quarterly either in cash, shares of common stock, or a combination thereof at the company's option, subject to certain equity conditions, on the 15th of April, July, October, and January of each year during the five year term of the notes, expiring June 2, 2027. The notes are convertible at any time and from time to time by the Holders into shares of common stock at a fixed conversion price of $0.13 per share. The company issued securities in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder.お知らせ • Mar 29ParkerVision, Inc. Announces that Orlando Court Grants Qualcomm Motion for Summary JudgmentParkerVision, Inc. announced that on March 22, 2022, the U.S. District Court in the Middle District of Florida ruled in Qualcomm’s favor on a motion styled as Qualcomm’s motion for “non-infringement and invalidity” (Dkt. 494) in ParkerVision v. Qualcomm (Case no. 6:14-cv-00687). The court’s order, which is sealed “for attorney’s eyes only,” determines that Qualcomm does not infringe the asserted claims of the remaining three patents-in-suit. It makes no findings as to the invalidity of any of the asserted claims of the remaining three patents-in-suit. This is a final order, meaning the next step is an appeal. ParkerVision intends to appeal this ruling, along with this same court’s March 9, 2022 ruling excluding opinions of the Company’s experts regarding infringement and validity issues.お知らせ • Mar 31ParkerVision, Inc. announced that it has received $3.6 million in fundingParkerVision, Inc. (OTCPK:PRKR) announced a private placement of units at an issue price of $1.29 per unit for gross priceeds of $3,600,000 on March 29, 2021. Each unit consists of one common share and half warrant. Each warrant is exercisable into shares at an exercise p[rice of $1.75 per share for a period of five years.お知らせ • Oct 05Parkervision Inc. to Report Q4, 2009 Results on 03/15/2010Parkervision Inc. announced that they will report Q4, 2009 results on 03/15/2010お知らせ • Aug 22+ 1 more updateParkerVision, Inc. announced that it has received $0.352701 million in funding from Gem Investment Advisors, LLCOn August 21, 2020, ParkerVision, Inc. closed the transaction. The company received $352,700 pursuant to regulation D.お知らせ • Aug 07+ 1 more updateParkerVision, Inc. announced that it has received $0.1745 million in fundingOn August 6, 2020, ParkerVision, Inc. (OTCPK:PRKR) closed the transaction. The transaction included participation from 3 investors.お知らせ • Jul 07ParkerVision, Inc. announced that it has received $0.215201 million in fundingParkerVision, Inc. (OTCPK:PRKR) announced that it has entered into securities purchase agreements to issue 614,859 shares at a price of $0.35 per share for gross proceeds of $215,201 on June 29, 2020. The purchase agreements also provide the investors with a contingent payment right whereby the company will pay each investor an allocated portion of the company’s net proceeds from its patent claims, after taking into account fees and expenses payable to law firms representing the company and amounts payable to the company’s litigation financer. The transaction will include participation from individual investors including Dennis Mehiel for 285,715 shares amounting to $100,000, Aileen Gregoire for 100,000 shares amounting to $35,000, Wenyu Luo for 85,715 amounting to $30,000, John Birdsall & Margaret Mintz for 72,000 amounting to $25,200, Manal Eldumiati for 71,429 amounting to $25,000. The shares will be offered and sold on a private placement basis under Section 4(a)(2) of the Securities Act of 1933 and Rule 506. The company received funding from 7 investors pursuant to Regulation D.決済の安定と成長配当データの取得安定した配当: PRKRの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PRKRの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場ParkerVision 配当利回り対市場PRKR 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PRKR)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Communications)1.7%アナリスト予想 (PRKR) (最長3年)n/a注目すべき配当: PRKRは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PRKRは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PRKRの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PRKRが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 14:58終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ParkerVision, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jon HickmanLadenburg Thalmann & Company
お知らせ • Nov 22ParkerVision, Inc. announced that it expects to receive $3.461132 million in fundingParkerVision, Inc. entered into subscription agreements with accredited investors on November 21, 2025. Pursuant to the agreement the Investors agreed to purchase an aggregate of 16,481,579 shares of the Company’s common stock, par value $0.01 per share, at a purchase price of $0.21 per share, for an aggregate purchase price of approximately $3,461,132. The closing of the transaction is expected to occur on November 24, 2025.
お知らせ • Aug 19ParkerVision, Inc., Annual General Meeting, Sep 30, 2025ParkerVision, Inc., Annual General Meeting, Sep 30, 2025.
お知らせ • Apr 22Parkervision, Inc. Announces Resignation of Sanford Litvack from Board of Directors, and from Audit and Compensation Committees, Effective April 15, 2025ParkerVision, Inc. announced thatoOn April 15, 2025, Mr. Sanford Litvack resigned from Board of Directors, and from the Audit and Compensation Committees on which he served.
お知らせ • Sep 07ParkerVision, Inc. Announces Appellate Court Overturns District Court in A Precedential Ruling, Sends Parkervision V Qualcomm Back to Florida for TrialParkerVision, Inc. announced that the United States Court of Appeals for the Federal Circuit (CAFC) has issued a favorable ruling in ParkerVision v. Qualcomm (Case No. 2022-1755). The CAFC upheld ParkerVision's position on each of the appealed issues and has sent the case back to the Middle District of Florida (District Court) for trial. The CAFC opinion: Reversed the District Court's Daubert ruling, which had deemed ParkerVision's expert report inadmissible and likewise vacated the District Court's grant of summary judgement of non-infringement of the transmitter claims which was based on the exclusion of ParkerVision's infringement experts. The District Court had dismissed the evidence supporting ParkerVision's patent infringement claims because the expert did not create his own simulations of Qualcomm's accused radio frequency chips. However, the CAFC found that the District Court abused its discretion in excluding the testimony of ParkerVision's validity expert, stating "the district court should have left it to jurors to evaluate the correctness of facts underlying an expert's testimony". This reversal reinstates ParkerVision's expert report, allowing the Company to present its infringement claims against Qualcomm to a jury. Vacated the District Court's summary judgement ruling, which had barred ParkerVision from asserting its radio frequency receiver patents in this case. The lower court had based its decision on the argument that these patents are essentially the same as other ParkerVision receiver patents previously asserted against Qualcomm in 2011. The CAFC found that the District Court erred in its determination that the asserted receiver claims did not have a scope that is materially different from the claims at issue in the 2011 case and remanded for further consideration. Reversed the District Court's application of collateral estoppel, which prevented ParkerVision from defending the validity of its ‘940 patent using arguments it previously presented to the Patent Trial and Appeal Board (PTAB) and the CAFC. These arguments had been successful in a prior inter partes review (IPR) proceeding initiated by Qualcomm in 2015 which delayed the patent infringement case until 2019. The CAFC has remanded the case to the U.S. District Court for the Middle District of Florida, ordering the reopening of the original case (Case No. 6:14-cv-00687). ParkerVision initiated this case against Qualcomm in the Federal District Court in Orlando, Florida, in May 2014 while awaiting a final decision on a separate 2011 patent infringement case involving different receiver patents. The case experienced several delays due to Qualcomm's IPR challenges to patent validity and court closures caused by the pandemic. By May 2021, all final pre-trial motions had been filed. With courts reopening in 2022, the District Court held a pre-trial motion hearing in January 2022, signaling preparation for a near-term jury trial. However, in March 2022, the District Court issued orders in Qualcomm's favor on all motions, effectively barring ParkerVision from presenting the case to a jury. The court subsequently closed the case file. ParkerVision appealed three of the District Court's rulings to the CAFC, and by the end of 2022, both parties had submitted their appellate briefs and replies. In November 2023, the CAFC permitted oral arguments to support these briefs. However, in July 2024, the CAFC found that it lacked proper jurisdiction over the case because the District Court had not issued a final order on Qualcomm's counterclaims for invalidity. Subsequently, the parties filed a joint motion with the District Court. On August 1, 2024, the District Court issued an order dismissing Qualcomm's invalidity counterclaims, without prejudice, clearing the way for the CAFC to proceed with its ruling on the appeal.
お知らせ • Sep 02ParkerVision, Inc., Annual General Meeting, Oct 28, 2024ParkerVision, Inc., Annual General Meeting, Oct 28, 2024.
お知らせ • Aug 03ParkerVision, Inc., Annual General Meeting, Sep 15, 2023ParkerVision, Inc., Annual General Meeting, Sep 15, 2023, at 11:00 Eastern Standard Time. Agenda: To elect two Class I directors until the term of Class I directors ends in 2026 and to elect one Class II director until the term of Class II directors ends in 2024; to approve, on an advisory basis, the company’s named executive officer compensation ("Say on Pay"); to ratify the selection of MSL, P.A. as the company’s independent registered public accounting firm for the year ending December 31, 2023; and to discuss other matters.
お知らせ • Jun 27ParkerVision, Inc. Appoints Lewis (Lew) H. Titterton as Class II DirectorParkerVision, Inc. announced that it has appointed Mr. Lewis (Lew) H. Titterton, Jr. as a Class II director to fill a vacancy on the company's board of directors. Mr. Titterton previously served on the ParkerVision board from September 2018 until April 2019 when he resigned due to family medical issues. Mr. Titterton has served on the board of directors of Anixa Biosciences since July 2017, including as lead independent director since July 2018 and chairman of the board from 2012 to 2016. His background is in high technology with an emphasis on health care and he was the chairman of the board of directors of NYMED, Inc. from 1989 until October 2018. Mr. Titterton founded MedE America, Inc. in 1986 and was the chief executive officer of Management and Planning Services, Inc. from 1978 to 1986. He holds an MBA from the State University of New York at Albany, and a B.A. degree from Cornell University.
お知らせ • Jan 24ParkerVision, Inc. announced that it has received $0.835 million in fundingOn January 23, 2023, ParkerVision, Inc. closed the transaction. The transaction included participation from five investors.
お知らせ • Jan 10ParkerVision, Inc. announced that it has received $1 million in fundingOn January 9, 2023, ParkerVision, Inc. closed the transaction. The transaction included participation from a single investor
お知らせ • Dec 16ParkerVision, Inc. announced that it has received $0.2 million in fundingOn December 14, 2022, ParkerVision, Inc. closed the transaction. The transaction included participation from a single investor.
お知らせ • Nov 01ParkerVision, Inc. Appoints Sanford M. Litvack as Board of DirectorParkerVision, Inc. announced that it has named Sanford (Sandy) Litvack to its Board of Directors, expanding the Board to five members, four of whom are independent. Mr. Litvack is a partner with Chaffetz Lindsey LLP and has a broad corporate litigation background, handling a wide array of complex matters, including patent and other intellectual property issues. Litvack served as Assistant Attorney General in charge of the Antitrust Division of the Department of Justice and was selected by President George W. Bush to serve as a member of the Antitrust Modernization Commission. In addition to his courtroom experience, Mr. Litvack spent a decade at the Walt Disney Company holding various roles from general counsel to chief of corporate operations and vice chairman of the board of directors. He is also a former director of Hewlett Packard. Mr. Litvack currently serves on the board of directors for L Catterton Asia Acquisition Corp., a special purpose acquisition company.
お知らせ • Aug 18ParkerVision, Inc. announced that it has received $1.6675 million in fundingOn August 17, 2022, ParkerVision, Inc. closed the transaction. The transaction included participation from 13 investors.
お知らせ • Aug 03ParkerVision, Inc., Annual General Meeting, Sep 16, 2022ParkerVision, Inc., Annual General Meeting, Sep 16, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect two Class III members of the Board to hold office until the third ensuing annual meeting and until his respective successor is duly elected and qualified; to approve an amendment to the amended and restated articles of incorporation of the company, as amended, to increase the number of authorized shares of common stock from 150,000,000 shares to 175,000,000 shares; to ratify the appointment of MSL, P.A. as the company's independent registered public accounting firm for the year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
お知らせ • Jul 02ParkerVision, Inc. announced that it has received $0.35 million in funding from Forge Trust Company, and other investorsParkerVision, Inc. announced that it has entered into a purchase agreement for a private placement of 8% unsecured convertible promissory notes for gross proceeds of $350,000on June 30, 2022. The transaction included participation from Forge Trust Company for $200,000, The Trustee of the Judson Dean LaCapra Revocable Trust for $25,000, individual investors John F. Levy for $100,000, Wilhem Boulay for $25,000. The notes bear interest at a fixed rate of 8% per annum and is payable quarterly either in cash, shares of common stock, or a combination thereof at the company's option, subject to certain equity conditions, on the 15th of April, July, October, and January of each year during the five year term of the notes, expiring June 30, 2027. The notes are convertible at any time and from time to time by the Holders into shares of common stock at a fixed conversion price of $0.13 per share. The company issued securities in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder.
お知らせ • Jun 03ParkerVision, Inc. announced that it has received $0.76 million in funding from Alpine Partners (Bvi), L.P., Thomas Staz Revocable TrustParkerVision, Inc. announced that it has entered into a note and warrant purchase agreement for a private placement of 8% unsecured convertible promissory notes for gross proceeds of $760,000 on June 2, 2022. The transaction included participation from Thomas Staz Revocable Trust for $65,000, Alpine Partners (BVI) LP for $500,000, individual investors, Harold Wrobel for $130,000 and Ronald T. Bevans, Jr. for $65,000. The notes bear interest at a fixed rate of 8% per annum and is payable quarterly either in cash, shares of common stock, or a combination thereof at the company's option, subject to certain equity conditions, on the 15th of April, July, October, and January of each year during the five year term of the notes, expiring June 2, 2027. The notes are convertible at any time and from time to time by the Holders into shares of common stock at a fixed conversion price of $0.13 per share. The company issued securities in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder.
お知らせ • Mar 29ParkerVision, Inc. Announces that Orlando Court Grants Qualcomm Motion for Summary JudgmentParkerVision, Inc. announced that on March 22, 2022, the U.S. District Court in the Middle District of Florida ruled in Qualcomm’s favor on a motion styled as Qualcomm’s motion for “non-infringement and invalidity” (Dkt. 494) in ParkerVision v. Qualcomm (Case no. 6:14-cv-00687). The court’s order, which is sealed “for attorney’s eyes only,” determines that Qualcomm does not infringe the asserted claims of the remaining three patents-in-suit. It makes no findings as to the invalidity of any of the asserted claims of the remaining three patents-in-suit. This is a final order, meaning the next step is an appeal. ParkerVision intends to appeal this ruling, along with this same court’s March 9, 2022 ruling excluding opinions of the Company’s experts regarding infringement and validity issues.
お知らせ • Mar 31ParkerVision, Inc. announced that it has received $3.6 million in fundingParkerVision, Inc. (OTCPK:PRKR) announced a private placement of units at an issue price of $1.29 per unit for gross priceeds of $3,600,000 on March 29, 2021. Each unit consists of one common share and half warrant. Each warrant is exercisable into shares at an exercise p[rice of $1.75 per share for a period of five years.
お知らせ • Oct 05Parkervision Inc. to Report Q4, 2009 Results on 03/15/2010Parkervision Inc. announced that they will report Q4, 2009 results on 03/15/2010
お知らせ • Aug 22+ 1 more updateParkerVision, Inc. announced that it has received $0.352701 million in funding from Gem Investment Advisors, LLCOn August 21, 2020, ParkerVision, Inc. closed the transaction. The company received $352,700 pursuant to regulation D.
お知らせ • Aug 07+ 1 more updateParkerVision, Inc. announced that it has received $0.1745 million in fundingOn August 6, 2020, ParkerVision, Inc. (OTCPK:PRKR) closed the transaction. The transaction included participation from 3 investors.
お知らせ • Jul 07ParkerVision, Inc. announced that it has received $0.215201 million in fundingParkerVision, Inc. (OTCPK:PRKR) announced that it has entered into securities purchase agreements to issue 614,859 shares at a price of $0.35 per share for gross proceeds of $215,201 on June 29, 2020. The purchase agreements also provide the investors with a contingent payment right whereby the company will pay each investor an allocated portion of the company’s net proceeds from its patent claims, after taking into account fees and expenses payable to law firms representing the company and amounts payable to the company’s litigation financer. The transaction will include participation from individual investors including Dennis Mehiel for 285,715 shares amounting to $100,000, Aileen Gregoire for 100,000 shares amounting to $35,000, Wenyu Luo for 85,715 amounting to $30,000, John Birdsall & Margaret Mintz for 72,000 amounting to $25,200, Manal Eldumiati for 71,429 amounting to $25,000. The shares will be offered and sold on a private placement basis under Section 4(a)(2) of the Securities Act of 1933 and Rule 506. The company received funding from 7 investors pursuant to Regulation D.